• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS)

  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


             

OSB Lead-Obalon Balloon System PAS


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Progress Adequate
Application Number P160001 S003/ PAS001
Date Current Protocol Accepted  
Study Name OSB Lead-Obalon Balloon System PAS
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group Device Subjects Serve as Own Control
Analysis Type Analytical
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Design Description Design: New enrollment, prospective, single arm, observational, sequentially enrolling, open label multi-center study.

Objective: The primary objective of the study is to assess the continued safety and performance of the Obalon Balloon System in the commercial setting.

Study Population Description In addition to the patients’ ability to commercially purchase the device, patients shall meet all inclusion criteria and no exclusion criteria to be considered eligible for study enrollment.



Inclusion Criteria

1. Minimum 22 years of age

2. BMI of 30.0-40.0 kg/m2

3. Previously attempted to lose weight unsuccessfully using a medically supervised or non-medically supervised diet

4. Study enrollment before or within 7 days of the initial balloon administration.



Exclusion Criteria

1. Contraindicated for use of the Obalon Balloon System per Obalon Balloon System,

Instructions for Use (LIT-7500-0011, page 3)

2. Use of medications or medical devices known to induce weight gain or weight loss within the preceding 6 months.

3. Known history of endocrine disorders affecting weight.

4. Participation in any clinical study which could affect weight loss within the past year.

5. Known history or present condition of structural or functional disorders of the

esophagus that may impede passage of the device through the gastrointestinal tract, including, Barrett’s esophagus, esophagitis, dysphagia, achalasia,

stricture/stenosis, esophageal varices, diverticula, or any other disorder of the

esophagus.

6. Life expectancy less than 1 year or severe renal, hepatic, pulmonary or other medical condition, in the opinion of the investigator.

Sample Size The study will include 15 sites in the United States. A total of 200 subjects will be enrolled, including a minimum of 50 patients receiving the porcine gelatin capsules and a minimum of 50 patients receiving the hydroxy propyl methyl cellulose (HPMC) capsules. Of the enrolled subjects, 180 are needed with data through 6 months.
Data Collection Primary and Secondary Endpoints Safety Endpoints

The study primary endpoint is a safety endpoint that evaluates the percentage of

subjects who experience a Serious Adverse Event that is device or procedure related.



Device or Procedure Related Serious Adverse Event Rate

The percentage of subjects who experience a Serious Adverse Event that is device or procedure related will be evaluated.



Effectiveness Endpoints

This trial is designed to evaluate co-secondary effectiveness endpoints comprised of

(1) the mean % TWL and (2) the proportion of subjects achieving at least 5% TWL.



Co-Secondary Endpoint: Mean Percent Total Weight Loss

The mean percent Total Weight Loss (%TWL) will be evaluated as the first portion of the co-primary endpoint. %TWL is calculated as the ratio of a subject’s weight loss to their starting weight as measured on the date of their first course, first administration procedure.



Co-Secondary Endpoint: 5% TWL Responder Rate

The responder rate will be evaluated as the second portion of the co-secondary endpoint. For the purpose of this co-secondary endpoint, a responder is defined as a subject that achieves at least 5% TWL based on their starting weight as measured on the date of receiving their first balloon.

Follow-up Visits and Length of Follow-up 52 weeks.



Patient participation time includes up to 4 weeks for screening, 24 weeks of balloon therapy period and 24 weeks post-balloon removal. Patients will be followed after post-balloon removal regardless of weight loss results during balloon therapy period.



OSB Lead-Obalon Balloon System PAS Schedule

Report Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
six month report 10/24/2017 09/11/2017 On Time
one year report 04/25/2018    
18 month report 10/24/2018    
two year report 04/25/2019    
three year report 04/24/2020    
four year report 04/24/2021    
five year report 04/24/2022    


Contact Us

Julie Unger
Project Manager, Post-Approval Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-4206v Silver Spring, MD
20993-0002

Phone: (301) 796-6134
Fax: (301) 847-8140
julie.unger@fda.hhs.gov

Related Links

-
-